Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX

Blood

Volumn 112, Issue 12, 2008, Pages 4532-4541

  Sun, Junjiang ^a   Hakobyan, Narine ^b,c   Valentino, Leonard A ^b,c   Feldman, Brian L ^a   Samulski, R Jude ^a   Monahan, Paul E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b RUSH Hemophilia and Thrombophilia Center   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SYNOVIAL FLUID LEVEL; GENE REPLACEMENT THERAPY; HEMARTHROSIS; HEMOPHILIA B; HEMOPHILIC SYNOVITIS; KNEE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; SURVIVAL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ARTHROPATHY; BIOAVAILABILITY; BLOOD; C57BL MOUSE; DISEASE MODEL; EVALUATION; GENE THERAPY; GENE VECTOR; GENETICS; INTRAARTICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE MUTANT; PATHOLOGY; SYNOVITIS;

ANIMALS; BIOLOGICAL AVAILABILITY; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FACTOR IX; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; HEMORRHAGE; INJECTIONS, INTRA-ARTICULAR; INJECTIONS, INTRAVENOUS; JOINT DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SYNOVITIS;

EID: 58149378469     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-131417     Document Type: Article

References (64)

1. Roosendaal G, van den Berg HM, Lafeber FP, Bjilsma J. Blood-induced joint damage: an overview of musculoskeletal research in haemophilia. In: Rodriguez-Merchan EC, Goddard NJ, Lee CA, eds. Musculoskeletal Aspects of Haemophilia. Oxford, United Kingdom: Blackwell Science; 2000:18.
2. Luck JV, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12: 234-245.
3. Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol. 2006;43[Suppl]:S18-S22.
4. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia. 2006; 12[Suppl 3]:117-121.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs: the Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391-399.
6. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol. 2007;136: 777-787.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis vs episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535-544.
8. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia. 2006;12:154-162.
9. Mulder K, Llinas A. The target joint. Haemophilia. 2004;10[Suppl 4]:152-156.
10. Rodriguez-Merchan EC, Magallon M, Galindo E, Lopez-Cabarcos C. Hemophilic synovitis of the knee and the elbow. Clin Orthop. 1997:47-53.
11. Shupak R, Teitel J, Garvey MB, Freedman J. Intraarticular methylprednisolone therapy in hemophilic arthropathy. Am J Hematol. 1988;27:26-29.
12. Wallny T, Brackmann HH, Semper H, et al. Intra-articular hyaluronic acid in the treatment of haemophilic arthropathy of the knee: clinical, radiological and sonographical assessment. Haemophilia. 2000;6:566-570.
13. Fernandez-Palazzi F, Rivas S, Viso R, de Bosch NB, de Saez AR, Boadas A. Synovectomy with rifampicine in haemophilic haemarthrosis. Haemophilia. 2000;6:562-565.
14. Manco-Johnson MJ, Nuss R, Lear J, et al. 32P Radiosynoviorthesis in children with hemophilia. J Pediatr Hematol Oncol. 2002;24:534-539.
15. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261.
16. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342-347.
17. Madry H, Cucchiarini M, Terwilliger EF, Trippel SB. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondro-cytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther. 2003;14:393-402.
18. Pan RY, Chen SL, Xiao X, Liu DW, Peng HJ, Tsao YP. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum. 2000;43:289-297.
19. Ulrich-Vinther M, Stengaard C, Schwarz EM, Goldring MB, Soballe K. Adeno-associated vector mediated gene transfer of transforming growth factor-beta1 to normal and osteoarthritic human chondrocytes stimulates cartilage anabolism. Eur Cell Mater. 2005;10:40-50.
20. Watanabe S, Imagawa T, Boivin GP, Gao G, Wilson JM, Hirsch R. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther. 2000;2:147-152.
21. Zhang HG, Xie J, Yang P, et al. Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther. 2000;11: 2431-2442.
22. Jin DY, Zhang TP, Gui T, Stafford DW, Monahan PE. Creation of a mouse expressing defective human factor IX. Blood. 2004;104:1733-1739.
23. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocom-petent mice by adeno-associated virus vector. J Virol. 1996;70:8098-8108.
24. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol. 1998;72: 10222-10226.
25. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90:3962-3966.
26. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia. 2008;14:804-809.
27. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia. 2006;12:654-662.
28. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia. 2004;10:280-287.
29. Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum. 2005;52:3248-3256.
30. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther. 2008;16: 280-289.
31. Bloquel C, Trollet C, Pradines E, Seguin J, Scherman D, Bureau MF. Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee. BMC Biotechnol. 2006;6:16.
32. Cheung WF, Wolberg AS, Stafford DW, Smith KJ. Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX. Thromb Res. 1995;80:419-427.
33. Sun J, Hakobyan N, Valentino LA, Monahan PE. Extravascular clotting factor within joint tissues protects against progression of hemophilic arthropathy. Blood. 2007;110:153a.
34. Liles D, Landen CN, Monroe DM, et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost. 1997;77:944-948.
35. Russell KE, Olsen EH, Raymer RA, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003; 102:4393-4398.
36. Gui T, Lin HF, Jin DY, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood. 2002;100:153-158.
37. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073-1080.
38. Zhang TP, Jin DY, Wardrop RM 3rd, et al. Trans-gene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Ther. 2007;14:429-440.
39. Banta JV, Boone DC, Smith CF. Arthrocentesis of the knee in acute hemophilic arthropathy. West J Med. 1975;122:285-288.
40. Goater J, Muller R, Kollias G, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol. 2000;27: 983-989.
41. Anklesaria P, Heald AE, Mease PJ. Intraarticular administration of a recombinant adeno-associated virus vector containing a TNF antagonist gene was safe, well tolerated and demonstrated trend in clinical response in subjects with inflammatory arthritis. Mol Ther. 2008;16[Suppl]:S111-S112.
42. Boissier MC, Lemeiter D, Clavel C, et al. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends onAAV serotype. Hum Gene Ther. 2007;18:525-535.
43. Apparailly F, Khoury M, Vervoordeldonk MJ, et al. Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther. 2005;16:426-434.
44. Khoury M, Adriaansen J, Vervoordeldonk MJ, et al. Inflammation-inducible anti-TNF gene expression mediated by intraarticular injection of sero-type 5 adeno-associated virus reduces arthritis. J Gene Med. 2007;9:596-604.
45. Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ, Tak PP. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J Gen Virol. 2007;88:1717-1721.
46. Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002;107:271-276.
47. Ronday HK, Smits HH, Van Muijen GN, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1996;35:416-423.
48. Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis. 2000;59:781-787.
49. Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34: 996-1005.
50. Chang P, Aronson DL, Borenstein DG, Kessler CM. Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. Am J Hematol. 1995;50:79-83.
51. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost. 2007;5:1577-1583.
52. Pollock LE, Lalor P, Revell PA. Type IV collagen and laminin in the synovial intimal layer: an immunohistochemical study. Rheumatol Int. 1990;9: 277-280.
53. Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem. 1997;272: 16717-16720.
54. Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol. 2005;25:2273-2281.
55. Fareed J, Callas DD, Hoppensteadt D, Bermes EW Jr. Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis. 1995; 6[suppl 1]:S32-S36.
56. Fan L, Yotov WV, Zhu T, et al. Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties. J Thromb Haemost. 2005;3:1056-1063.
57. Furmaniak-Kazmierczak E, Cooke TD, Manuel R, et al. Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. J Clin Invest. 1994;94:472-480.
58. Naldini A, Bernini C, Pucci A, Carraro F. Thrombin-mediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes. J Leukoc Biol. 2005;78:736-744.
59. Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I. Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. Ann Rheum Dis. 2002;61:834-837.
60. McDonald AG, Yang K, Roberts HR, Monroe DM, Hoffman M. Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood. 2008;111: 2046-2048.
61. Traister RS, Fabre S, Wang Z, Xiao X, Hirsch R. Inflammatory cytokine regulation of transgene expression in human fibroblast-like synoviocytes infected with adeno-associated virus. Arthritis Rheum. 2006;54:2119-2126.
62. Herzog RW. Gene therapy and the immune system. Curr Gene Ther. 2007;7:296.
63. Hooiveld MJ, Roosendaal G, Jacobs KM, et al. Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy. Arthritis Rheum. 2004;50:2024-2031.
64. Sarkar R, Mucci M, Addya S, et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther. 2006;17:427-439.